Long-Acting Compstatin Analogs for Sustained Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for complement-mediated disorders are inadequate in providing long-lasting inhibition of complement activation, leading to persistent tissue damage and disease progression.
Innovation Solution
Development of long-acting compstatin analogs with specific dosing regimens to effectively inhibit complement activation in various disorders, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, ischemia/reperfusion injury, and chronic respiratory disorders, by administering compositions comprising these analogs in physiologically acceptable forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing treatments are used for complement-mediated disorders, then treatment can be administered, but long-lasting inhibition of complement activation is not achieved
Solution Approach 1:
The patent modifies the chemical structure of compstatin by conjugating it to carrier proteins (such as albumin or immunoglobulins) or by PEGylation, thereby changing the pharmacokinetic parameters of the drug. This structural modification extends the half-life and duration of action of compstatin, enabling long-lasting complement inhibition without compromising its ability to bind C3 and inhibit complement activation.
2Duration of action of moving object
If long-acting compstatin analogs are developed, then sustained complement inhibition is achieved, but treatment complexity increases
Solution Approach 1:
The patent uses carrier proteins (such as albumin or immunoglobulins) as intermediaries to extend the circulation time of compstatin. The carrier protein acts as a mediator that protects compstatin from rapid clearance while maintaining its biological activity. This approach simplifies the treatment regimen by enabling less frequent dosing compared to unmodified compstatin, despite the additional conjugation step in manufacturing.
Data Source
AI summary
In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.